CD8A and neoplasm: The altered cancer glycome actively engages in the crosstalk between tumors and immune cells, and targeting tumor‐associated glycosylation has been suggested to enhance antitumor immunity [40]. For example, blocking sialylation in tumor cells enhances the maturation of DCs and promotes the CD8 T cell‐mediated killing of tumor cells in vivo [41].